Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229216 | 0.94 | GCGR (0.47) | GCGRALDH1A1HTTSHMT2MAPT | |
| SCHEMBL950735 | 0.87 | GCGR (0.42) | GCGRALDH1A1HTTMAPTTP53 | |
| SCHEMBL4230649 | 0.74 | GCGR (0.42) | GCGRALDH1A1HTTMAPTTP53 | |
| SCHEMBL950833 | 0.72 | ALDH1A1 (0.53) | GCGRALDH1A1HTTMAPTTP53 | |
| Deuterium Oxide SCHEMBL952591 | 0.71 | MAPT (0.49) | GCGRALDH1A1HTTMAPTTP53 | |
| SCHEMBL4502610 | 0.71 | MAPT (0.40) | GCGRALDH1A1MAPTTP53GAA | |
| SCHEMBL949980 | 0.70 | ALDH1A1 (0.53) | GCGRALDH1A1HTTMAPTTP53 | |
| SCHEMBL949686 | 0.70 | MAPT (0.45) | GCGRALDH1A1HTTMAPTTP53 | |
| SCHEMBL3840369 | 0.69 | GCGR (0.38) | GCGRALDH1A1HTTMAPTTP53 | |
| SCHEMBL4598474 | 0.68 | MAPT (0.39) | GCGRALDH1A1HTTMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-1994010-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC18A2, SLC1A2, SLC1A1 | GCGR 571/4885ALDH1A1 974/4885HTT 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.